Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue exceeding $25 billion. Its Mission is to enable our customers to make the world healthier, cleaner and safer. Whether the customers are accelerating life sciences research, solving complex analytical challenges, improving patient diagnostics and therapies or increasing productivity in their laboratories, the company is here to support them. Its global team of more than 75,000 colleagues delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services and Patheon.
Company profile
Ticker
TMO
Exchange
Website
CEO
Marc Casper
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Rockwell Automation • Trimble • Cubic • MTS Systems • Faro • Geospace Technologies • Onto Innovation • Owlet • 908 Devices • Autoscope Technologies ...
Former names
THERMO ELECTRON CORP
SEC CIK
Corporate docs
Subsidiaries
Thermo Fisher Scientific Operating Company LLC • Thermo Fisher Scientific Senior Financing LLC • Thermo Fisher Scientific (DE) Holding S.a.r.l. • Laboratory Management Systems, Inc. • Thermo Fisher Scientific Peru S.R.L. • Thermo Fisher Scientific Malaysia Sdn. Bhd. • Fisher Clinical Logistics LLC • Fisher Clinical Services (Suzhou) Co., Ltd. • Fisher Clinical Services Limited Liability Company • Fisher Clinical Services (Korea) Co., Ltd ...
IRS number
42209186
TMO stock data
Analyst ratings and price targets
Latest filings (excl ownership)
IRAN
Disclosure regarding Iran Threat Reduction and Syria Human Rights Act
23 Feb 23
10-K
2022 FY
Annual report
23 Feb 23
8-K
Thermo Fisher Scientific Reports Fourth Quarter and Full Year 2022 Results
1 Feb 23
CERT
Certification of approval for exchange listing
22 Nov 22
8-A12B
Registration of securities on exchange
21 Nov 22
8-K
Entry into a Material Definitive Agreement
21 Nov 22
424B5
Prospectus supplement for primary offering
15 Nov 22
424B5
Prospectus supplement for primary offering
15 Nov 22
FWP
Free writing prospectus
14 Nov 22
8-K
Departure of Directors or Certain Officers
14 Nov 22
Transcripts
TMO
Earnings call transcript
2022 Q4
1 Feb 23
TMO
Earnings call transcript
2022 Q3
26 Oct 22
TMO
Earnings call transcript
2022 Q2
28 Jul 22
TMO
Earnings call transcript
2022 Q1
28 Apr 22
TMO
Earnings call transcript
2021 Q4
2 Feb 22
TMO
Earnings call transcript
2021 Q3
27 Oct 21
TMO
Earnings call transcript
2021 Q2
28 Jul 21
TMO
Earnings call transcript
2021 Q1
29 Apr 21
TMO
Earnings call transcript
2020 Q4
1 Feb 21
TMO
Earnings call transcript
2020 Q3
21 Oct 20
Latest ownership filings
4
MARC N CASPER
15 Mar 23
144
Notice of proposed sale of securities
14 Mar 23
144
Notice of proposed sale of securities
13 Mar 23
4
Michel Lagarde
7 Mar 23
4
Gianluca Pettiti
7 Mar 23
4
Stephen Williamson
2 Mar 23
4
Gianluca Pettiti
2 Mar 23
4
Michel Lagarde
2 Mar 23
4
Joseph R. Holmes
2 Mar 23
4
MARC N CASPER
2 Mar 23
Financial summary
| Quarter (USD) | Dec 22 | Oct 22 | Jul 22 | Apr 22 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
Institutional ownership, Q4 2022
88.9% owned by funds/institutions
| 13F holders | Current |
|---|---|
| Total holders | 2297 |
| Opened positions | 223 |
| Closed positions | 130 |
| Increased positions | 842 |
| Reduced positions | 893 |
| 13F shares | Current |
|---|---|
| Total value | 187.77 tn |
| Total shares | 342.79 mm |
| Total puts | 2.28 mm |
| Total calls | 2.58 mm |
| Total put/call ratio | 0.9 |
| Largest owners | Shares | Value |
|---|---|---|
| Vanguard | 32.53 mm | $17.92 tn |
| BLK Blackrock | 30.79 mm | $16.96 tn |
| STT State Street | 16.29 mm | $8.97 tn |
| Capital World Investors | 13.55 mm | $7.46 tn |
| MS Morgan Stanley | 11.73 mm | $6.46 tn |
| FMR | 11.16 mm | $6.15 tn |
| Massachusetts Financial Services | 9.29 mm | $5.12 tn |
| T. Rowe Price | 9.12 mm | $5.03 tn |
| Capital Research Global Investors | 7.16 mm | $3.94 tn |
| Geode Capital Management | 6.88 mm | $3.79 tn |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 14 Mar 23 | Casper Marc N | Common Stock | Sell | Dispose S | Yes | Yes | 560.95 | 100 | 56.10 k | 59,155 |
| 14 Mar 23 | Casper Marc N | Common Stock | Sell | Dispose S | Yes | Yes | 559.94 | 100 | 55.99 k | 59,255 |
| 14 Mar 23 | Casper Marc N | Common Stock | Sell | Dispose S | Yes | Yes | 559.03 | 400 | 223.61 k | 59,355 |
| 14 Mar 23 | Casper Marc N | Common Stock | Sell | Dispose S | Yes | Yes | 558.04 | 800 | 446.43 k | 59,755 |
| 14 Mar 23 | Casper Marc N | Common Stock | Sell | Dispose S | Yes | Yes | 556.9 | 560 | 311.86 k | 60,555 |
| 14 Mar 23 | Casper Marc N | Common Stock | Sell | Dispose S | Yes | Yes | 555.8 | 400 | 222.32 k | 61,115 |
| 14 Mar 23 | Casper Marc N | Common Stock | Sell | Dispose S | Yes | Yes | 554.86 | 850 | 471.63 k | 61,515 |
| 14 Mar 23 | Casper Marc N | Common Stock | Sell | Dispose S | Yes | Yes | 553.57 | 667 | 369.23 k | 62,365 |
| 14 Mar 23 | Casper Marc N | Common Stock | Sell | Dispose S | Yes | Yes | 552.41 | 1,200 | 662.89 k | 63,032 |
| 14 Mar 23 | Casper Marc N | Common Stock | Sell | Dispose S | Yes | Yes | 551.51 | 840 | 463.27 k | 64,232 |
News
Thermo Fisher Scientific And Arsenal Biosciences Announced An Update To Their Strategic Collaboration To Further The Development Of Manufacturing Processes For New Cancer Treatments
29 Mar 23
Reported Late Monday March 27, Thermo Fisher Scientific Opens Cell Therapy Facility At University Of California, San Francisco, To Accelerate Development Of Breakthrough Therapies
28 Mar 23
Thermo Fisher Scientific Unusual Options Activity
22 Mar 23
'Thermo Fisher, Celltrion Vie For Baxter's Biopharma Unit -Sources' - Reuters News
21 Mar 23
Stevanato Has Collaborated With Thermo Fisher Scientific To Bring To The Market A Fully Integrated On-body Delivery System Platform For Subcutaneous Administration
21 Mar 23
Press releases
Thermo Fisher Scientific Opens Cell Therapy Facility at University of California, San Francisco, to Accelerate Development of Breakthrough Therapies
27 Mar 23
Mark Stevenson Joins General Atlantic as Senior Advisor Focused on Life Sciences
24 Mar 23
ASLAN Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
24 Mar 23
GeminiBio Appoints Industry Veteran Cory Stevenson as Executive Chairman
16 Mar 23
Resolve Biosciences Announces Appointment of John Stark as Chief Executive Officer
15 Mar 23